Table 1 Baseline characteristics and efficacy data of patient cohort analyzed for BCNU-related side effects
Patient Characteristics | |
|---|---|
Patient Sample [n] | 163 |
Age at onset of BCNU therapy [years] (median; range) | 44 (17–81) |
Sex [male:female; n] | 108:55 |
Karnofsky Performance Score [%] (median; range) | 80 (20–100) |
Histology [number of patients] (%) | |
Glioblastoma WHO grade IV | 84 (51,5) |
Oligodendroglioma WHO grade III | 30 (18,4) |
Oligoastrocytoma WHO grade III | 14 (8,6) |
Astrocytoma WHO grade III | 13 (8) |
Oligodendroglioma WHO grade II | 12 (7,4) |
Oligoastrocytoma WHO grade II | 3 (1,8) |
Astrocytoma WHO grade II | 7 (4,3) |
Median OS [months] | |
WHO grade II tumors | 191 |
WHO grade III tumors | 144 |
WHO grade IV tumors | 20 |
Median PFSBCNU [months] | |
WHO grade II tumors | 85 |
WHO grade III tumors | 28 |
WHO grade IV tumors | 7 |
Death [number of patients] (%) | |
WHO grade II tumors | 9 (41) |
WHO grade III tumors | 37 (65) |
WHO grade IV tumors | 82 (98) |
Lost to follow up [number of patients] (%) | |
WHO grade II tumors | 5 (23) |
WHO grade III tumors | 13 (23) |
WHO grade IV tumors | 1 (1) |
Pre-treatment [number of patients] (%) | |
Radiotherapy | 147 (90) |
Temozolomide | 20 (12,2) |
PCV | 4 (2,4) |
Methotrexate | 2 (1,2) |
BCNU – total dose [mg] (median; range) | 1662 (300–5200) |
BCNU – number of cycles (median; range) | 5 (1–16) |
BCNU-related side effects [number of patients] (%) | 88 (54) |
WHO grade II tumors | 18 (82) |
WHO grade III tumors | 35 (61) |
WHO grade IV tumors | 35 (42) |
BCNU – dose reduction to due side effects (%) | 48 (29,4) |
BCNU – Hospital admission due to side effects (%) | 2 (1,2) |
Chemotherapy-related deaths (%) | 0 |